Tumor and Organ Dose Estimates from 177Lu-PSMA-617 Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Results from the RESIST-PC Phase 2 Trial.

Zachary Ells¹, Catherine Meyer², Karam Masri², Marc Ryhiner^2,3, David Sennung², Koichiro Kimura², David Mirando⁴, Izabela Tworowska⁵, Rouzbeh Esfandiari⁶, Martin S Allen-Auerbach², Michael Lassmann⁷, Ken Herrmann^8,9, Matthias Eiber^10,11, Wolfgang P Fendler^8,9, Ebrahim Delpassand^5,6, Johannes Czernin², Magnus Dahlbom², Jeremie Calais²

¹Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California; zells@mednet.ucla.edu.

²Department of Nuclear Medicine and Theranostics, Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.

³Department of Nuclear Medicine, Inselspital, University of Bern, Bern, Switzerland.

⁴MIM Software, Beachwood, Ohio.

⁵RadioMedix Inc., Houston, Texas.

⁶Excel Diagnostics & Nuclear Oncology Center, Houston, Texas.

⁷Department of Nuclear Medicine, Würzburg University Hospital, Würzburg, Germany.

⁸University of Essen, Essen, Germany.

⁹Department of Nuclear Medicine, West German Cancer Center, DKTK and NCT site, University Hospital Essen, Essen, Germany.

¹⁰Technical University of Munich, Munich, Germany; and.

¹¹Bavarian Cancer Research Center, Erlangen, Germany.

PubMed DOI

Abstract

This is a dosimetry analysis of the prospective randomized phase 2 trial RESIST-PC which evaluated the efficacy and safety of 2 injected activity regimens of [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer. Methods: This biinstitutional study randomized patients with metastatic castration-resistant prostate cancer to receive either 6.0 or 7.4 GBq of…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.